Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Completed · Phase 1

Conditions studied: Intraocular Melanoma, Melanoma (Skin)

In brief

RATIONALE: Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Giving the vaccine in different ways may make a stronger immune response and kill more tumor cells. PURPOSE: This randomized clinical trial is studying two different ways of giving vaccine therapy to compare how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma.

Key facts

Study ID
NCT00398073
Run by
Memorial Sloan Kettering Cancer Center
People needed
35
Starts
2006-10-01
Expected to finish
2011-03-01
Last updated by the study team
2017-03-16

Who can join

Age: 1 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.